Fragment growing exploiting dynamic combinatorial chemistry of inhibitors of the aspartic protease endothiapepsin

Fragment-based drug design (FBDD) has emerged as an efficient hit-identification and/or -optimization strategy with a higher hit rate than high-throughput screening (HTS). Whereas fragment linking is more challenging, fragment growing has become the preferred fragment-optimization strategy, requiring synthesis of derivatives and validation of their binding mode at each step of the optimization cycle. Dynamic combinatorial chemistry (DCC) is a powerful and efficient strategy to identify ligands for biological targets. Here, we have demonstrated that the novel combination of fragment-growing and DCC is a highly powerful strategy to grow a fragment into a more potent, non-covalent inhibitor of the aspartic protease endothiapepsin. We have designed a library of acylhydrazones using fragment growing starting from a known fragment in complex with endothiapepsin. We have used DCC and a fluorescence-based enzymatic assay to identify the best hit(s) from the dynamic combinatorial libraries, displaying double-digit micromolar inhibition of endothiapepsin. In addition, each DCC experiment requires only very small amounts of protein compared with established methods of analysis and the protein needs to be in the assay mixture only for a short period of time, making this protocol ideal for precious and unstable proteins. These results constitute a proof of concept that the combination of fragment growing and DCC is a powerful and efficient strategy to convert a fragment into a hit.

[1]  Paul G Wyatt,et al.  Detection of ligands from a dynamic combinatorial library by X-ray crystallography. , 2003, Angewandte Chemie.

[2]  Chris Abell,et al.  A Fragment‐Based Approach to Probing Adenosine Recognition Sites by Using Dynamic Combinatorial Chemistry , 2009, Chembiochem : a European journal of chemical biology.

[3]  D. Erlanson Fragment-based lead discovery: a chemical update. , 2006, Current opinion in biotechnology.

[4]  Gerhard Klebe,et al.  Structure-based design of inhibitors of the aspartic protease endothiapepsin by exploiting dynamic combinatorial chemistry. , 2014, Angewandte Chemie.

[5]  J. Cooper,et al.  A neutron Laue diffraction study of endothiapepsin: implications for the aspartic proteinase mechanism. , 2001, Biochemistry.

[6]  Leighton Coates,et al.  X-ray, neutron and NMR studies of the catalytic mechanism of aspartic proteinases , 2006, European Biophysics Journal.

[7]  Rutger H A Folmer,et al.  Discovery of a novel warhead against beta-secretase through fragment-based lead generation. , 2007, Journal of medicinal chemistry.

[8]  M. Congreve,et al.  Recent developments in fragment-based drug discovery. , 2008, Journal of medicinal chemistry.

[9]  Rob Leurs,et al.  Transforming fragments into candidates: small becomes big in medicinal chemistry. , 2009, Drug discovery today.

[10]  Christopher J. Schofield,et al.  Selective Inhibitors of the JMJD2 Histone Demethylases: Combined Nondenaturing Mass Spectrometric Screening and Crystallographic Approaches† , 2010, Journal of medicinal chemistry.

[11]  T. James,et al.  Asymmetric Strecker synthesis of α-arylglycines. , 2011, The Journal of organic chemistry.

[12]  Yuan Cheng,et al.  From fragment screening to in vivo efficacy: optimization of a series of 2-aminoquinolines as potent inhibitors of beta-site amyloid precursor protein cleaving enzyme 1 (BACE1). , 2011, Journal of medicinal chemistry.

[13]  Xiang Li,et al.  Fragment-based discovery of indole inhibitors of matrix metalloproteinase-13. , 2011, Journal of medicinal chemistry.

[14]  Christopher J Schofield,et al.  Dynamic combinatorial mass spectrometry leads to metallo-beta-lactamase inhibitors. , 2008, Journal of medicinal chemistry.

[15]  Rob Leurs,et al.  Fragment growing induces conformational changes in acetylcholine-binding protein: a structural and thermodynamic analysis. , 2011, Journal of the American Chemical Society.

[16]  Milon Mondal,et al.  Dynamic combinatorial chemistry: a tool to facilitate the identification of inhibitors for protein targets. , 2015, Chemical Society reviews.

[17]  L. Mario Amzel,et al.  Impact of linker strain and flexibility in the design of a fragment-based inhibitor , 2009, Nature chemical biology.

[18]  Daniel A Erlanson,et al.  Discovery of an Aurora kinase inhibitor through site-specific dynamic combinatorial chemistry. , 2008, Bioorganic & medicinal chemistry letters.

[19]  P. Hajduk,et al.  A decade of fragment-based drug design: strategic advances and lessons learned , 2007, Nature Reviews Drug Discovery.

[20]  T. Blundell,et al.  X-ray crystallographic analysis of inhibition of endothiapepsin by cyclohexyl renin inhibitors. , 1992, Biochemistry.

[21]  Paul R. Gerber,et al.  MAB, a generally applicable molecular force field for structure modelling in medicinal chemistry , 1995, J. Comput. Aided Mol. Des..

[22]  Gerhard Klebe,et al.  A small nonrule of 3 compatible fragment library provides high hit rate of endothiapepsin crystal structures with various fragment chemotypes. , 2011, Journal of medicinal chemistry.

[23]  M. Congreve,et al.  A 'rule of three' for fragment-based lead discovery? , 2003, Drug discovery today.

[24]  Dominic J Campopiano,et al.  Bivalent enzyme inhibitors discovered using dynamic covalent chemistry. , 2012, Chemistry.

[25]  H. Cheng,et al.  The power issue: determination of KB or Ki from IC50. A closer look at the Cheng-Prusoff equation, the Schild plot and related power equations. , 2001, Journal of pharmacological and toxicological methods.

[26]  Andreas Herrmann,et al.  Dynamic combinatorial/covalent chemistry: a tool to read, generate and modulate the bioactivity of compounds and compound mixtures. , 2014, Chemical Society reviews.

[27]  J. Lehn,et al.  Virtual combinatorial libraries: dynamic generation of molecular and supramolecular diversity by self-assembly. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[28]  Gianni Chessari,et al.  From fragment to clinical candidate--a historical perspective. , 2009, Drug discovery today.

[29]  G. Marshall,et al.  A simple, continuous fluorometric assay for HIV protease. , 2009, International journal of peptide and protein research.

[30]  Jon Cooper,et al.  The catalytic mechanism of an aspartic proteinase explored with neutron and X-ray diffraction. , 2008, Journal of the American Chemical Society.

[31]  Torsten Luksch,et al.  Nucleophilic catalysis of acylhydrazone equilibration for protein-directed dynamic covalent chemistry. , 2010, Nature chemistry.